The Caring Ambassadors supports individuals in gaining control of their health care, regardless of the illness they face.

We provide information, tools, and resources to help those with any chronic health condition not only manage their health care after a diagnosis, but improve their quality of life and capacity for healing. As an advocacy organization, we both fight for patient rights and work to build a new generation of patient and health care champions. Our disease specific programs for Hepatitis C and Lung Cancer have been helping people obtain the support, assistance, and information they need for over 20 years.

To receive our weekly news updates in your inbox, CLICK HERE

Hepatitis C News
Week Ending September 9, 2019

Prevalence of Hepatitis C and the Risk for Cardiovascular Disease in Relation to Income
‘Patients with a hepatitis C virus (HCV) infection have an increased risk for cardiovascular disease (CVD), with the highest burden placed on low-income and middle-income countries. This is according to a study in the Lancet Gastroenterology & Hepatology.’

Elevated fatty liver index in HCV/HIV coinfection predicts mortality risk
‘Researchers discovered that an elevated fatty liver index was an independent risk factor for all-cause mortality in patients coinfected with hepatitis C and HIV, regardless of liver fibrosis or sustained virologic response to hepatitis therapy.’

FDA approves label changes for Sovaldi, Harvoni in children with HCV
‘The FDA approved changes to the labeling of direct-acting antivirals Sovaldi and Harvoni to include information on dosage and administration in pediatric patients with hepatitis C aged 3 years to younger than 12 years.’

Amino Acid Variants Responsible for Reduced Response to Hepatitis C Treatment
‘New insights show why a certain hepatitis C virus (HCV) genotype is resistant to a common drug used to treat the viral infection. An investigative team, including Peter A.C. Wing, PhD, Barts Liver Centre, Blizard Institute Queen Mary University of London, collected patient serum samples from the HCV Research UK Biobank and used capture-fusion assay techniques to assess viral sensitivity to sofosbuvir in 14 HCV genotype 3 samples.’

Ledipasvir/Sofosbuvir looks good in HBV-coinfected patients
‘For patients with chronic hepatitis C and hepatitis B virus co-infection, 12 weeks of ledipasvir/sofosbuvir therapy achieved a 100 percent sustained viral response rate without causing liver failure or death in a phase 3b, multicenter, open-label study.’

Resistance-guided HCV retreatment achieves nearly 90% SVR
‘Resistance-guided direct-acting antiviral retreatment resulted in nearly 90% sustained virologic response rates among patients with hepatitis C who developed resistance-associated substitutions after failing treatment with NS5A inhibitors.’

Lung Cancer News
Week Ending September 9, 2019

IASLC World Conference on Lung Cancer–Summary of the Presidential Symposium Research
This is a summary of research presented this morning at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.

KEYNOTE 189: Tumor Mutational Burden Not Significantly Associated with Efficacy of Pembrolizumab
Barcelona— Tumor mutational burden was not significantly associated with efficacy of pembrolizumabplus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamousnon-small cell lung cancer, according to research reported today by Dr. M. Garassino from theFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Dr. Garassino presented this new datatoday at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association forthe Study of Lung Cancer.

Survey reveals ‘suboptimal awareness’ of lung cancer molecular testing guidelines
BARCELONA — One-third of health care professionals reported a lack of knowledge about evidence-based guidelines for molecular testing of lung cancer, according to survey results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Amgen drug shrinks lung cancer tumors in half of patients: study
(Reuters) – An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.

Lung Ambition Alliance unveils new initiatives to aress lung cancer survival at the World Conference on Lung Cancer
BARCELONA, Spain, Sept.07, 2019(GLOBE NEWSWIRE) — Today, at the IASLC World Conference on Lung Cancer, the four founding partners of the Lung Ambition Alliance – the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca – announced the launch of several new initiatives to support their goal of doubling 5-year survival by 2025.

Researchers identify mutations associated with treatment sensitivity, resistance in NSCLC
BARCELONA —STK11 and KEAP1 mutations appeared associated with poorer outcomes among patients with metastatic non-small cell lung cancer regardless of treatment with chemotherapy or immunotherapy, according to results of an exploratory analysis of the phase 3 MYSTIC trial presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

IASLC: All physicians should screen patients with cancer for tobacco use
BARCELONA — The International Association for the Study of Lung Cancer, or IASLC, today issued a declaration at its World Conference on Lung Cancer advising all physicians to screen their patients with cancer for tobacco use and recommend tobacco cessation.

Why more ex-smokers, and smokers, should take CT lung cancer test
The warnings are old hat by now: According to the Centers for Disease Control and Prevention, smoking causes about 1 in 5 deaths in the United States each year. Despite nationwide decreases in smoking over the decades, lighting up remains the country’s leading cause of preventable disease.

Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful
ZURICH (Reuters) – Novartis has nabbed the U.S. Food and Drug Administration’s breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer < in the race to treat a tough-to-treat mutated lung cancer type.

Promising Early Results for a “Chemo-Free” Frontline Combination Regimen in Patients With Advanced NSCLC
An overall response rate (ORR) of 72.7% was observed in an interim analysis of a phase 1 study evaluating the combination of sintilimab, an inhibitor of the programmed cell death-1 (PD-1) receptor, and anlotinib, a tyrosine kinase inhibitor (TKI), for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).

Artificial Intelligence Boosts Clinical Trial Enrollment in Lung Cancer
Results of a study evaluating the use of artificial intelligence for matching oncology patients with clinical trials showed a 58.4% increase in trial enrollment compared with traditional screening methods.

Afatinib Continues to Showcase Activity in NRG1 Fusions in Lung Cancer
Findings from a small case series of patients with lung cancer added to evidence that afatinib (Gilotrif) is a potentially effective treatment in patients with lung adenocarcinoma who have NRG1 fusions, according to a poster presentation during the 2019 World Conference on Lung Cancer.

Astra’s Imfinzi Shows Positive Signs in Deadly Lung Cancer
An AstraZeneca Plc medicine called Imfinzi showed that it can offer a new treatment option for one of the most deadly forms of lung cancer.

Integrative Health & Medicine News
Week Ending September 9, 2019

September is Pain Awareness Month
“Serious illness is often accompanied by pain and controlling that pain can be difficult. Seeing a loved one experiencing pain and distress is hard on caregivers, too, who want their loved ones to get consistent and reliable relief to be able to live comfortably and enjoy good quality of life.”

Why You Don’t Need a Lot of Time or Money to Make Self-Care a Priority
“Self-care is a term thrown around a lot, but experts say it’s often misunderstood.”

Toxins, the environment, and your health
“Good lifestyle choices — exercising regularly, eating a healthy diet, not smoking, and drinking in moderation — obviously makes a big difference in staying healthy. Research in the last few decades has shown, however, that environmental exposures may also contribute to major diseases and health problems that disproportionately affect men, including heart disease, prostate cancer, infertility, and skin cancer.”

5 ways your diet affects neurological health
“We’re all familiar with the effects an unhealthy diet can have on our hearts and waistlines. Study after study have shown that a diet high in ultra-processed foods (think added sugars, preservatives and chemical additives) can lead to obesity, cardiovascular disease, diabetes and a shorter lifespan — just to name a few of the downsides.”

Everything you need to know about cupping, a traditional Chinese medical technique
“Cupping is a traditional Chinese medical technique popularized by athletes — recall Michael Phelps at the 2016 Olympics — that uses suction cups to release tension from muscles.”

Use Food To Stay Healthy This Fall
“Have you noticed that summer’s heat is gradually fading? You step outside during the evening hours and experience a cooler night. When you breath in the cool air, something inside of you knows that the seasons are shifting.”

Vegetarian heart health: Study identifies benefits and risks
“The authors of a large, long term study conclude that pescatarianism and vegetarianism have an association with a reduced risk of ischemic heart disease, but they note that vegetarians have a slightly higher risk of stroke.”